Capstone Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capstone Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-10,900	Closed	-$952K	–	2101
2024 Q1	$952K	Hold	10,900	–	–	﹤0.01%	1180
2023 Q4	$1.05M	Hold	10,900	–	–	﹤0.01%	1035
2023 Q3	$964K	Hold	10,900	–	–	﹤0.01%	996
2023 Q2	$945K	Sell	10,900 -29	-0.3%	-$2.73K	﹤0.01%	890
2023 Q1	$1.06M	Buy	10,929 +29	+0.3%	+$3.01K	0.01%	772
2022 Q4	$1.13M	Hold	10,900	–	–	0.01%	889
2022 Q3	$924K	Hold	10,900	–	–	0.01%	1062
2022 Q2	$903K	Buy	10,900 +8,212	+306%	+$654K	﹤0.01%	1057
2022 Q1	$207K	Buy	+2,688	New	+$225K	﹤0.01%	1690
2021 Q2	–	Sell	-12,000	Closed	-$951K	–	1720
2021 Q1	$906K	Sell	12,000 -4,235	-26%	-$346K	﹤0.01%	1156
2020 Q4	$1.42M	Buy	16,235 +1,831	+13%	+$145K	﹤0.01%	971
2020 Q3	$1.1M	Sell	14,404 -8,742	-38%	-$884K	0.01%	990
2020 Q2	$2.85M	Sell	23,146 -4,854	-17%	-$482K	0.02%	597
2020 Q1	$2.37M	Sell	28,000 -500	-2%	-$43.1K	0.04%	470
2019 Q4	$2.41M	Buy	28,500 +6,000	+27%	+$453K	0.01%	781
2019 Q3	$1.52M	Sell	22,500 -9,500	-30%	-$732K	0.01%	799
2019 Q2	$2.74M	Sell	32,000 -2,000	-6%	-$171K	0.02%	652
2019 Q1	$3.02M	Sell	34,000 -1,000	-3%	-$92.7K	0.03%	484
2018 Q4	$2.98M	Buy	+35,000	New	+$3.33M	0.04%	362
2018 Q2	–	Sell	-6,500	Closed	-$527K	–	687
2018 Q1	$527K	Buy	+6,500	New	+$558K	0.01%	266
2017 Q4	–	Sell	-14,200	Closed	-$1.32M	–	508
2017 Q3	$1.32M	Buy	+14,200	New	+$1.25M	0.05%	190
2016 Q1	–	Sell	-5,242	Closed	-$549K	–	648
2015 Q4	$549K	Sell	5,242 -2,799	-35%	-$292K	0.01%	331
2015 Q3	$846K	Buy	+8,041	New	+$1.07M	0.02%	237
2015 Q2	–	Sell	-18,500	Closed	-$2.31M	–	293
2015 Q1	$2.31M	Buy	+18,500	New	+$1.96M	0.04%	198

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capstone Investment Advisors's BMRN Position: Q2 2024 in Review

Capstone Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 10,900 shares — an estimated $952K sold.

Capstone Investment Advisors first reported a position in BMRN in Q1 2015 and held it in 24 quarters. The position peaked at $3.02M in Q1 2019. 559 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

Capstone Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Capstone Investment Advisors sold 10,900 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $952K.
Capstone Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 24 quarters.
Capstone Investment Advisors's BioMarin Pharmaceuticals position peaked at $3.02M in Q1 2019.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Capstone Investment Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.